Am J Obstet Gynecol:诱导分娩:米索前列醇溶液该怎么使用

2017-05-17 吴星 环球医学

这些年已经积累了支持口服米索前列醇作为安全且廉价的药物用于诱导分娩的证据。2017年4月,发表在《Am J Obstet Gynecol》的一项由沙特阿拉伯科学家进行的研究,比较了每小时滴定和每2小时静口服米索前列醇溶液诱导生产的有效性和安全性。背景:米索前列醇是一种诱导分娩的有效药物。现有的指南推荐每2小时口服米索前列醇溶液25 μg。然而,需要更多研究以优化口服米索前列醇溶液用于诱导分娩。目的

这些年已经积累了支持口服米索前列醇作为安全且廉价的药物用于诱导分娩的证据。2017年4月,发表在《Am J Obstet Gynecol》的一项由沙特阿拉伯科学家进行的研究,比较了每小时滴定和每2小时静口服米索前列醇溶液诱导生产的有效性和安全性。

背景:米索前列醇是一种诱导分娩的有效药物。现有的指南推荐每2小时口服米索前列醇溶液25 μg。然而,需要更多研究以优化口服米索前列醇溶液用于诱导分娩。

目的:该研究的目的是比较每小时滴定剂量口服米索前列醇溶液与每2小时静态剂量口服米索前列醇溶液用于诱导分娩的有效性和安全性。

研究设计:在这项随机对照研究中,口服米索前列醇溶液按照(1)每小时20 μg(≤4剂),缺乏规律的子宫收缩时增加至每小时40 μg(≤4剂),然后增加至每小时60 μg(≤16剂),或每2小时25 μg直至开始积极生产(≤12剂)。计划样本量为146例女性,每小时滴定剂量米索前列醇溶液使用率达到95%,每2小时静态剂量米索前列醇溶液使用率达到80%为主要终点(24小时内阴道分娩)。安全结局包括母亲死亡率和新生儿不良结局。

结果:从2013年12月至2015年7月,146例女性被随机分配治疗。除了年龄以外,两组的人口特征和临床特征相似。47例(64.4%)使用每小时滴定剂量米索前列醇溶液的女性和48例(65.8%)使用每2小时静态剂量米索前列醇溶液的女性在24小时内成功实现阴道分娩(P=1.00)。未生育过的女性(P=1.00)或过期妊娠(P=0.66)、Bishop评分≤3(P=0.84)或催产素增加(P=0.83)的女性不同治疗组之间24小时内阴道分娩率没有显着差异。9例使用每小时滴定剂量米索前列醇溶液的女性和2例使用每2小时静态剂量米索前列醇溶液的女性在24小时内行剖宫产(P=0.056)。使用每小时滴定剂量米索前列醇溶液的女性发热和胎粪染色的发生频率更高。

结论:每2小时静态剂量口服米索前列醇溶液的有效性与每小时滴定剂量米索前列醇溶液相似,但副作用较少,并发症发生率更低。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2043957, encodeId=dde7204395e34, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 27 03:13:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934064, encodeId=a7081934064ba, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Mon Feb 19 16:13:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011294, encodeId=fb8e201129418, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Dec 31 06:13:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275104, encodeId=952d12e5104c7, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 19 07:13:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199340, encodeId=19e219934086, content=好好学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 17 22:02:53 CST 2017, time=2017-05-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2043957, encodeId=dde7204395e34, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 27 03:13:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934064, encodeId=a7081934064ba, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Mon Feb 19 16:13:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011294, encodeId=fb8e201129418, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Dec 31 06:13:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275104, encodeId=952d12e5104c7, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 19 07:13:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199340, encodeId=19e219934086, content=好好学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 17 22:02:53 CST 2017, time=2017-05-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2043957, encodeId=dde7204395e34, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 27 03:13:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934064, encodeId=a7081934064ba, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Mon Feb 19 16:13:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011294, encodeId=fb8e201129418, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Dec 31 06:13:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275104, encodeId=952d12e5104c7, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 19 07:13:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199340, encodeId=19e219934086, content=好好学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 17 22:02:53 CST 2017, time=2017-05-17, status=1, ipAttribution=)]
    2017-12-31 yhy100200
  4. [GetPortalCommentsPageByObjectIdResponse(id=2043957, encodeId=dde7204395e34, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 27 03:13:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934064, encodeId=a7081934064ba, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Mon Feb 19 16:13:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011294, encodeId=fb8e201129418, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Dec 31 06:13:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275104, encodeId=952d12e5104c7, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 19 07:13:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199340, encodeId=19e219934086, content=好好学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 17 22:02:53 CST 2017, time=2017-05-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2043957, encodeId=dde7204395e34, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 27 03:13:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934064, encodeId=a7081934064ba, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Mon Feb 19 16:13:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011294, encodeId=fb8e201129418, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Dec 31 06:13:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275104, encodeId=952d12e5104c7, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri May 19 07:13:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199340, encodeId=19e219934086, content=好好学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed May 17 22:02:53 CST 2017, time=2017-05-17, status=1, ipAttribution=)]
    2017-05-17 I come

    好好学习,谢谢分享

    0

相关资讯

Lancet:口服米索前列醇或使用Foley尿管引产的结果是类似的

所有妊娠的20-30%都是催产的。对于子宫颈情况不好的女性,与地诺前列酮阴道分娩相比,两种口服米索前列醇和Foley导尿管都同样有效,但每种方法都有更好的安全性。研究人员做了一个试验,直接比较了单独口服米索前列醇与Foley尿管的结果。原始出处:Mieke L G ten Eikelder,Katrien Oude Rengerink,Marta Jozwiak,et al.Induction o

Obstet Gynecol:催产素联合米索前列醇能减少产后出血吗?

由此可见,米索前列醇联合预防性常规催产素使用并没有降低产后出血风险率,反而提高了产妇不良事件的发生率。

同时服用米索前列醇与非甾体抗炎药可以减少心血管疾病的风险

根据一项研究计划提交的研究,针对胃肠溃的疡药,将米索前列醇与非甾体抗炎药(NSAID)共同服用的患者比单独服用NSAIDs的患者具有显着降低严重心血管、中风和肾衰竭的风险。

妊娠早期流产的药物处理(临床指南)

2014年3月,第143号(代替Practice Bulletin 2005年10月,第67号) 在过去三十年里,药物流产方法在世界各地得到发展,也是目前在美国流产的标准方法。药物流产是使用药物而非外科手术来进行流产的,适用于妊娠早期希望终止妊娠的妇女。虽然药物流产最常用于最多孕63天(从末次月经第一天开始计算)内,但在孕63天后该方法也有效。疾病控制和预防中心估计64%的流产在孕6

BMJ:米索前列醇用于妊娠引产的安全性和有效性

目的 评估前列腺素用于妊娠引产的安全性和有效性 数据来源:The Cochrane Pregnancy 和 Childbirth Group's Database of Trials(包含一个广泛的通用搜索所有妊娠和产后试验)。数据来源于CENTRAL, Medline, Embase, NHS Economic Evaluation Database, CINAHL, relevant jou

Lancet:对于不全流产的处理,助产士不逊于医师

对于不全流产的治疗临床上通常会首选米索前列醇,但是在资源缺乏的环境中,助产士在使用该药治疗不全流产时,通常不会进行系统性的评估。因此Klingberg-Allvin M等研究者调查了助产士在诊断不全流产和使用米索前列醇治疗不全流产时的有效性和安全性,与医师对其的处理相比是否有差异。